Highlights the significant burden of venous thromboembolism in cancer patients, which varies considerably depending on the primary malignancy.
Answers are grounded in this paper and cite their sources.
May warrant heightened VTE vigilance in pancreatic/lung cancer; leaves open type-specific prophylaxis trials.
An hypercoagulable state frequently accompanies malignancy, due to the ability of tumor cells to activate the coagulation system, which leads to thrombosis that is responsible for the second cause of mortality in cancer patients. A four-fold increase of thrombotic risk occurs in cancer, and the increase is even greater during chemotherapy. A clinically detectable venous thromboembolism was detected in 15% of all cancer patients. Some cancers are more likely to be prothrombotic (prevalence is 27-28%, in pancreas and lung, 13% in stomach, but only 3% in colon cancer).
No takes yet. Share an insight, caveat, or question.
Mirshahi S Pritchard LL (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: